Myocarditis

Revision as of 19:56, 24 February 2021 by ClaireLewis (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

This page is for adult patients. For pediatric patients, see: myocarditis (peds)

Background

  • Inflammatory (dilated) cardiomyopathy caused by necrosis of myocytes

Causes

Phases

  • Acute
    • Viral cytotoxicity and focal necrosis
  • Subacute
    • Host's humoral/immune response leading to further cell injury
  • Chronic
    • Diffuse myocardial fibrosis and cardiac dysfunction

Clinical Features

  • Consider this diagnosis in the septic-appearing patient who gets WORSE after receiving IV fluids

Differential Diagnosis

Consider other causes of CHF

Chest pain

Critical

Emergent

Nonemergent

Evaluation

Management

  • Acute phase
    • Antiviral agents (Pleconaril/Ribavirin) may be effective
    • COVID-related: limited/conflicting evidence regarding efficacy of high-dose steroids and/or IVIG [2]
  • Subacute phase
    • Studies have not shown efficacy of immunosupressants
    • Pediatric patients may receive high-dose IVIG
  • Chronic phase
    • Treatment for CHF symptoms
    • Ventricular Assist Devices (VAD)
    • Cardiac transplant

Disposition

  • If CHF is present, admit to monitored bed
  • If hemodynamically unstable, admit to ICU

Prognosis

  • Fulminant myocarditis has best prognosis
  • Mortality: 20% 1 yr/ 50% 5 yr
  • Children with 70% survival rate at 5 yrs

Complications

See Also

References